PT ENSEVAL PUTERA MEGATRADING Tbk COMPANY UPDATE YTD 31 MARCH 2010 RESULTS

Size: px

Start display at page:

Download "PT ENSEVAL PUTERA MEGATRADING Tbk COMPANY UPDATE YTD 31 MARCH 2010 RESULTS"

Bonnie Warner
6 years ago
Views:

1 PT ENSEVAL PUTERA MEGATRADING Tbk COMPANY UPDATE YTD 31 MARCH 2010 RESULTS

2 Table of Contents Section I Section II Section III Section IV Enseval In Brief Business Overview Operational Highlights Financial Highlights

3 I. Enseval In Brief

Milestones Responding to the government regulation which require separation between role of distribution and role of marketing / manufacturing, PT Enseval was established in October 1973 In 1993, PT

4 Milestones Responding to the government regulation which require separation between role of distribution and role of marketing / manufacturing, PT Enseval was established in October 1973 In 1993, PT Enseval transferred all trading and distribution businesses to PT Arya Gupta Cempaka, a wholly owned subsidiary, which later change its company name to PT Enseval Putera Megatrading On 1 August 1994, the Company was listed on Indonesian Stock Exchange

Medika Prima & PT Global Chemindo Megatrading 2008 Incorporation of PT Renalmed Tiara Utama in July

5 Milestones 1994 PT Enseval Putera Megatrading Tbk conducted its Initial Public Offering 2003 Incorporation of Subsidiary PT Milenia Dharma Insani 2007 Incorporation of Subsidiary : PT Enseval Medika Prima & PT Global Chemindo Megatrading 2008 Incorporation of PT Renalmed Tiara Utama in July PT Enseval Medika Prima, PT Global Chemindo Megatrading & PT Renalmed Tiara Utama started operations in October

6 Company Structures PT Enseval Putera Megatrading Tbk PT Enseval Putera Megatrading Tbk PT Tri Sapta Jaya 99.9% PT Milenia Dharma Insani 100.0% PT Enseval Medika Prima 100.0% PT Global Chemindo Megatrading 100.0% PT Renalmed Tiara Utama 97.5%

7 Distribution & Logistic Product Range : Ethical, OTC, Consumer Products, Medical Device & Raw Material Our service : Warehousing Inventory Management Freight & Transportation Sales & Support Order-taking, Billing & Collection

8 II. Business Overview

Distribution & Logistic Directly and Indirectly covers more than 1,000,000 outlets Direct delivery to end customers Cover most pharmacies & hospital Cover 80% of consumer & health market 24 hour

9 Distribution & Logistic Directly and Indirectly covers more than 1,000,000 outlets Direct delivery to end customers Cover most pharmacies & hospital Cover 80% of consumer & health market 24 hour order fulfillment & 4-5 hour order fulfillment for prescription pharma 24 hour service for life saving drug Offers value added services to customers : - resource management, strategic sourcing & supply - needs-basis marketing service

Medical Device Product Range : Consumables, Instruments, Laboratories & Diagnostics, and Products related to Laboratories Industry The Company offers Marketing services for medical devices through

10 Medical Device Product Range : Consumables, Instruments, Laboratories & Diagnostics, and Products related to Laboratories Industry The Company offers Marketing services for medical devices through its subsidiary, PT Enseval Medika Prima and Hemodialysis Treatment in collaboration with clinics and hospitals through PT Renalmed Tiara Utama. The company has retained the trust & maintained good relationships with multinational principals

extensive network and collaboration with Multinational Companies from different

11 Raw Material Related to : Pharmaceutical Product, Food, Cosmetics & Veterinary PT Global Chemindo Megatrading offers trading & marketing of raw material and has extensive network and collaboration with Multinational Companies from different countries, such as : United States, Europe, China, Japan, Korea and other countries.

Laboratory & Mini market, which now also offers

12 Healthcare Services Healthcare Services through Mitrasana Clinics,with facilities such as: Clinic, Pharmacy, Laboratory & Mini market, which now also offers Hemodialysis treatment. Until 31 December 2009, The Company has 17 Clinics

13 III. Operational Highlights

14 Events Highlights Infrastructures & Branches Development in branches, such as : Bekasi, Pematang Siantar. The Company awarded as Pharmaceutical distribution Company that has the most outlet from Rekor Bisnis Indonesia

15 Branches The largest pharmaceutical distribution network throughout the Indonesian Archipelago with 42 Branches (EPM), 2 Regional Distribution Center, Located in Jakarta & Surabaya & 23 Branches under subsidiary company (TSJ)

The Company continues to promote CONIM Program (Continuos

16 Human Resources Employs over 4,000 personnel with over 2,000 personnel are working in sales and distribution In year 2010, The Company continues to promote CONIM Program (Continuos Improvement) to all staffs, both in Headquarters & in all Branches.

17 Major Principals Principals Based on Categories Ethical OTC Consumers Product

18 Major Principals Principals Based on Categories Medical Devices & Diagnostic Raw Material Friesland Foods Domo

19 Infrastructures Approximately 650 Transportation Fleet Approximately 400 Motorcycles More than Pallets Size The Usage of Oracle System as IT Platform

20 IV. Financial Highlights

Financial Highlights Until YTD 31 March 2010, The Company recorded Net Sales of IDR 2.0 trillion, with Operating Income amounting to IDR 75.3 billion Net Sales Operating Income 10.0 8.0 6.0 4.0 2.0 0.

21 Financial Highlights Until YTD 31 March 2010, The Company recorded Net Sales of IDR 2.0 trillion, with Operating Income amounting to IDR 75.3 billion Net Sales Operating Income % % 15.7% % YTD 31 Mar % 15.0% 10.0% 5.0% 0.0% % 4.8% 5.7% 6.0% % 3.7% 4.0% YTD 31 Mar % 2.0% 1.0% 0.0% Operating Income (IDR Billion) Operating Income Margin NS ( IDR Trillion) Growth

22 Financial Highlights Until YTD 31 March 2009, The Company Net Income was IDR 52.1 million, decline 32.5% YoY with Net Income Per Share of IDR 23 Net Income Net Income Per Share % % % % YTD 31 Mar 10 Net Income (IDR Million) Net Profit Margin 4.5% 4.0% 3.5% 3.0% 2.5% 2.0% 1.5% 1.0% 0.5% 0.0% YTD 31 Mar 10 Net Income Per Share (IDR)

Net Sales By Division 759 4.8% 724 673 18.6% 568 348 10.6% 390 8.9% 152 167 93 18.8% 79 16.

23 Net Sales By Division % % % % % % 7 9 Consumer Products Ethical OTC Raw Material Medical Device Others YTD 31 Mar 2010 (IDR Billion) YTD 31 Mar 2009 (IDR Billion)

24 Sales Contribution Until YTD 31 Mar 10 Kalbe Group s Sales contributes 72% of total sales, while the remaining 28% are from 3 rd party Principals. 28% 72% 74% 26% Kalbe Grup 3rd Party YTD 31 Mar 2010 YTD 31 Mar 2009

37% OTC 20% Medical Device 4% Raw Material 9% Others 1%

25 Sales Contribution OTC 17% Medical Device 5% Raw Material 8% Others 0% YTD 31 Mar 2010 Consumer Products 37% OTC 20% Medical Device 4% Raw Material 9% Others 1% YTD 31 Mar 2009 Consumer Products 37% Ethical 33% Ethical 29%

Assets 2,793 19.0% 2,454 3,196 18.8% 2,843 403 17.

26 Assets 2, % 2,454 3, % 2, % Mar 10 (IDR Billion) 31 Mar 09 (IDR Billion) Current Assets Non Current Assets Total Assets

Liabilities & Equity 4.8% 7.8% 1,462 1,395 1,540 1,428 17.1% 1,656 1,414 134.

27 Liabilities & Equity 4.8% 7.8% 1,462 1,395 1,540 1, % 1,656 1, % Current Liablities Non Current Liabilities Total Liabilities 31 Mar 10(IDR Billion) 31 Mar 09 (IDR Billion) Equity 31 Dec 10 (IDR Billion) 31 Dec 09 (IDR Billion)

28 Thank You For further information, please contact : PT Enseval Putera Megatrading Tbk. Enseval Building, Kawasan Industri Pulogadung Jalan Pulolentut No.10 Jakarta Indonesia Phone : Fax : Website : investor.relations@enseval.com

29 IMPORTANT NOTICE This presentation has been prepared for informational purposes only by PT Enseval Putera Megatrading Tbk. ( Enseval or the Company ). The information contained in this Presentation does not purport to be all-inclusive or to contain all of the information that may be material to an investor s decision. It should be noted that the information contained in this Presentation is subjected to further review, and that such information may be updated and/or amended from time to time as circumstances change or more information becomes available. Some of those revisions or changes may be material. Each recipient of this Presentation should therefore perform their own independent analysis of the business, operations, financial condition, creditworthiness, status and affairs of Enseval. Each recipient should also conduct their own enquiries into the adequacy, accuracy, and completeness of any information relating to Enseval, as the information and data contained in this Presentation are not substitutes for the recipient s independent evaluation and analysis. This presentation is not an offering document and will be updated regularly as necessary.

Ensevalin Brief. Business Overview. Operational Highlights. Financial Highlights

Ensevalin Brief. Business Overview. Operational Highlights. Financial Highlights YTD 30 September 2009 Section I Section II Section III Section IV Ensevalin Brief Business Overview Operational Highlights Financial Highlights 1 I. Enseval In Brief Responding to the government regulation